Skip to main content
  • Saved

made a Post

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab - PubMed

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33980831/

doi: 10.1038/s41408-021-00478-4. 1 Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 2 Unité Hémopathies Lymphoïdes, CHU Henri Mondor, Créteil, France. 3 Service d'hématologie, CHRU Hôpitaux de Brabois, Nancy, France. 4 Département d'hématologie Clinique, Centre Hospitalier Universitaire de Montpellier, Montpellier, France. 5 Hematology Department, Nantes University Hospital, Nantes, France.